Kalydeco Marks the Latest Success of the Cystic Fibrosis Foundation’s Venture Philanthropy Model
Site Search
CF Foundation Provided Scientific, Clinical and Significant Funding Support in Drug Development Process
This medicine represents the single greatest therapeutic advancement in the history of CF, offering a treatment for the underlying cause of the disease that could eventually benefit more than 90 percent of people with CF.
Drugs that target the underlying defect in the cystic fibrosis transmembrane conductance regulator (
Cystic fibrosis affects people of every racial and ethnic group. Of the nearly 40,000 people living with CF in the U.S., approximately 15% are identified as racially or ethnically diverse. Research shows that people of color with CF, particularly people who are Black and Hispanic, experience unique challenges and often have negative experiences that can lead to poorer outcomes. Some of these inequities are referenced in the following data.
Drug Targets the Underlying Cause of the Disease in People with the Most Common CF Mutation
Estamos buscando tratamientos potenciales para las personas con FQ que tienen mutaciones raras y sin sentido. Es posible que no aprovechen de los moduladores, que corrigen la proteína reguladora de la conductancia transmembrana de la fibrosis quística (CFTR, por sus siglas en inglés) que funciona mal.